Trials / Unknown
UnknownNCT05089266
Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors
Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 nanobodies (αPD1-MSLN-CAR T cells) in patients with solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CAR T cells | αPD1-MSLN-CAR T Cells |
Timeline
- Start date
- 2021-11-30
- Primary completion
- 2024-07-30
- Completion
- 2025-01-30
- First posted
- 2021-10-22
- Last updated
- 2023-07-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05089266. Inclusion in this directory is not an endorsement.